Imiquimod

Generic Name
Imiquimod
Brand Names
Aldara, Vyloma, Zyclara
Drug Type
Small Molecule
Chemical Formula
C14H16N4
CAS Number
99011-02-6
Unique Ingredient Identifier
P1QW714R7M
Background

Imiquimod is an immune response modifier that acts as a toll-like receptor 7 agonist. Imiquimod is commonly used topically to treat warts on the skin of the genital and anal areas. Imiquimod does not cure warts, and new warts may appear during treatment. Imiquimod does not fight the viruses that cause warts directly, however, it does help to relieve and control wart production. Miquimod is also used to treat a skin condition of the face and scalp called actinic keratoses and certain types of skin cancer called superficial basal cell carcinoma.

Indication

For the topical treatment of clinically typical, nonhyperkeratotic, nonhypertrophic actinic keratoses on the face or scalp in immunocompetent adults. Also indicated for the treatment of external genital and perianal warts/condyloma acuminata in individuals 12 years old and above.

Associated Conditions
Actinic Keratoses of the face, Actinic Keratoses of the scalp, Condylomata Acuminata, Herpes Simplex Infections, Molluscum Contagiosum, Superficial Basal Cell Carcinoma
Associated Therapies
-

Imiquimod Plus Antimony Immunochemotherapy for Cutaneous Leishmaniasis

Phase 3
Completed
Conditions
First Posted Date
2005-11-23
Last Posted Date
2008-06-12
Lead Sponsor
Drugs for Neglected Diseases
Target Recruit Count
80
Registration Number
NCT00257530
Locations
🇵🇪

UPCH, Cusco, Peru

🇵🇪

IMT Alexander Von Humboldt, Lima, Peru

Safety and Efficacy Study of Imiquimod 5% Cream Applied 3x Per Week for 8 or 12 Weeks in Low Risk Nodular Basal Cell Carcinoma

Phase 4
Completed
Conditions
First Posted Date
2005-09-20
Last Posted Date
2011-09-01
Lead Sponsor
University Hospital Tuebingen
Target Recruit Count
100
Registration Number
NCT00204555
Locations
🇩🇪

Skin Cancer Program, Department of Dermatology, Liebermeisterstrasse 8, Tübingen, BW, Germany

Aldara for the Treatment of Large and/or Multiple sBCC

Phase 3
Completed
Conditions
Interventions
First Posted Date
2005-09-19
Last Posted Date
2022-02-22
Lead Sponsor
MEDA Pharma GmbH & Co. KG
Target Recruit Count
111
Registration Number
NCT00189280
Locations
🇫🇷

Service de DermatologieHôpital Dupuytren, Limoges, France

A Study to Evaluate Effectiveness of Imiquimod 5% Cream in Superficial Basal Cell Carcinoma

Phase 3
Completed
Conditions
First Posted Date
2005-09-19
Last Posted Date
2022-02-07
Lead Sponsor
MEDA Pharma GmbH & Co. KG
Target Recruit Count
160
Registration Number
NCT00189241
Locations
🇩🇪

Univertätsklinik für Dermatologie und Venerologie, Magedeburg, Germany

A Study to Follow up Recurrence Rates of Actinic Keratoses One Year After Completion of Study 1487-IMIQ

Completed
Conditions
Interventions
First Posted Date
2005-09-19
Last Posted Date
2022-02-07
Lead Sponsor
MEDA Pharma GmbH & Co. KG
Target Recruit Count
72
Registration Number
NCT00189254

Study of Imiquimod Cream Prior to Ablative Therapy in External Ano-Genital Warts

Phase 4
Completed
Conditions
Interventions
First Posted Date
2005-09-19
Last Posted Date
2022-02-07
Lead Sponsor
MEDA Pharma GmbH & Co. KG
Target Recruit Count
128
Registration Number
NCT00189293
Locations
🇮🇹

Unità Operativa di Ginecologia Oncologica, RCCS Ospedale Oncologico, Bari, Italy

🇮🇹

Servizio Autonomo di Diagnosi Precoce dei Tumori Ginecologici Ospedale Vittorio Emanuele, Catania, Italy

🇮🇹

Clinica Ostetrica Ginecologica, Ospedale Careggi, Firenze, Italy

and more 9 locations

Safety and Efficacy of Imiquimod Applied in Dose-Cycle for Actinic Keratoses

Phase 3
Completed
Conditions
First Posted Date
2005-09-15
Last Posted Date
2006-05-09
Lead Sponsor
University of British Columbia
Target Recruit Count
20
Registration Number
NCT00175643
Locations
🇨🇦

Clinical Trials Unit, Skin Care Centre, UBC Dermatology, Vancouver, British Columbia, Canada

NY-ESO-1 Protein Vaccine With Imiquimod in Melanoma (Adjuvant Setting)

First Posted Date
2005-09-02
Last Posted Date
2022-10-10
Lead Sponsor
Ludwig Institute for Cancer Research
Target Recruit Count
9
Registration Number
NCT00142454
Locations
🇺🇸

NYU Cancer Institute, New York, New York, United States

Vaccine Therapy With or Without Imiquimod in Treating Patients Who Have Undergone Surgery for Stage II, Stage III, or Stage IV Melanoma

Phase 1
Completed
Conditions
First Posted Date
2005-07-11
Last Posted Date
2020-03-27
Lead Sponsor
Craig L Slingluff, Jr
Registration Number
NCT00118313
Locations
🇺🇸

University of Virginia Cancer Center, Charlottesville, Virginia, United States

Imiquimod Cream in Treating Patients With Basal Cell Skin Cancer

Phase 1
Completed
Conditions
First Posted Date
2004-03-10
Last Posted Date
2013-04-26
Lead Sponsor
National Naval Medical Center
Registration Number
NCT00079300
Locations
🇺🇸

NIH - Warren Grant Magnuson Clinical Center, Bethesda, Maryland, United States

© Copyright 2024. All Rights Reserved by MedPath